Note the use of the words "if" and "fingers crossed". In business, those are not good words. Then scroll back to the previous posts. Do real DD and distinguish always between speculation, hope and dreaming. Then, when things don't quite add up, yet again, either go into a couple of CVS stores and you will learn of the absence of ActiPatch in the IMS or you could always just call and ask the right questions of the right people in procurement.
Failing all that, ask the questions and judge for yourself. Is it logical that if BIEL had solidified its commercial relationship with CVS beyond the trial phase they would not have announced that? Doing a deal with a chain of the magnitude of CVS would not warrant some news?
I supported what appeared to be a protective management news blackout for many months post FDA Clearances in Feb 2017, knowing how much competition there is in the pharma and retail industries. However, in time, as others entered the PEMF space, I became curious if BIEL was being tactically wise or floundering, unable to move ahead.
The solutions to stimulating BIEL's journey to the top of the heap are relatively easy, or virtually impossible without change. Doing the same thing over and over expecting different results is what? Enough with the Kool Aid. There is no crystal ball.
Curiosity formed with no retail chain deals at 6 months after clearance summer 2017 and grew at the end of 2017, how come no deals? Where is the Dr. Scholl's deal? Where is the KT Tape deal? Keith Nalepka interviews, great sales guy. Where are the closed deals? Who in their right mind defers a 3 pallet shipment? Who in their right mind defers anything? What's missing in the supply-chain? What happened to the CE Mark? And here we all are. What don't we know?
